[go: up one dir, main page]

MX2019007156A - Inhibidores de imidazopirazina de la tirosina cinasa de bruton. - Google Patents

Inhibidores de imidazopirazina de la tirosina cinasa de bruton.

Info

Publication number
MX2019007156A
MX2019007156A MX2019007156A MX2019007156A MX2019007156A MX 2019007156 A MX2019007156 A MX 2019007156A MX 2019007156 A MX2019007156 A MX 2019007156A MX 2019007156 A MX2019007156 A MX 2019007156A MX 2019007156 A MX2019007156 A MX 2019007156A
Authority
MX
Mexico
Prior art keywords
imidazopyrazine
inhibitors
tyrosine kinase
bruton tyrosine
compounds
Prior art date
Application number
MX2019007156A
Other languages
English (en)
Other versions
MX388457B (es
Inventor
Evarts Jerry
Kaptein Allard
Podoll Terry
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MX2019007156A publication Critical patent/MX2019007156A/es
Publication of MX388457B publication Critical patent/MX388457B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula (I) y (II) o una sal farmacéuticamente aceptable de los mismos, o a composiciones farmacéuticas que comprenden estos compuestos y a su uso en terapia. En particular, en algunas modalidades, la presente invención se refiere a los compuestos de Fórmula (I) y (II), composiciones farmacéuticas de los mismos, y al uso de los compuestos y composiciones farmacéuticas en el tratamiento de un trastorno hiperproliferativo, un trastorno inflamatorio, un trastorno inmune, o un trastorno autoinmune.
MX2019007156A 2016-12-21 2017-12-21 Inhibidores de imidazopirazina de la tirosina cinasa de bruton. MX388457B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437633P 2016-12-21 2016-12-21
US201762569028P 2017-10-06 2017-10-06
PCT/IB2017/058319 WO2018116259A1 (en) 2016-12-21 2017-12-21 Imidazopyrazine inhibitors of bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
MX2019007156A true MX2019007156A (es) 2019-09-05
MX388457B MX388457B (es) 2025-03-20

Family

ID=60972291

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007156A MX388457B (es) 2016-12-21 2017-12-21 Inhibidores de imidazopirazina de la tirosina cinasa de bruton.

Country Status (15)

Country Link
US (1) US10858364B2 (es)
EP (1) EP3558968B1 (es)
JP (1) JP7022131B2 (es)
KR (1) KR102559851B1 (es)
CN (1) CN110291080B (es)
AU (1) AU2017383236B2 (es)
CA (1) CA3046578A1 (es)
CL (1) CL2019001674A1 (es)
ES (1) ES2856248T3 (es)
IL (1) IL267374B (es)
MX (1) MX388457B (es)
MY (1) MY203083A (es)
SA (1) SA519402217B1 (es)
WO (1) WO2018116259A1 (es)
ZA (1) ZA201903932B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
SMT202200369T1 (it) 2015-11-19 2022-11-18 Incyte Corp Composti eterociclici come immunomodulatori
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
SG10202005790VA (en) 2015-12-22 2020-07-29 Incyte Corp Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
TW201808902A (zh) 2016-05-26 2018-03-16 美商英塞特公司 作為免疫調節劑之雜環化合物
SG11201811414TA (en) 2016-06-20 2019-01-30 Incyte Corp Heterocyclic compounds as immunomodulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
MA47099A (fr) 2016-12-22 2021-05-12 Incyte Corp Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
UA128453C2 (uk) 2018-03-30 2024-07-17 Інсайт Корпорейшн Гетероциклічні сполуки як імуномодулятори
PL3790877T3 (pl) 2018-05-11 2023-06-12 Incyte Corporation Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1
US11040031B2 (en) 2018-06-18 2021-06-22 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
MY206899A (en) 2018-08-29 2025-01-13 Acerta Pharma Bv Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
WO2021030162A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
CN115175734B (zh) 2019-09-30 2024-04-19 因赛特公司 作为免疫调节剂的吡啶并[3,2-d]嘧啶化合物
CA3160131A1 (en) 2019-11-11 2021-05-20 Incyte Corporation Salts and crystalline forms of a pd-1/pd-l1 inhibitor
CN114075190A (zh) * 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂
US11760756B2 (en) 2020-11-06 2023-09-19 Incyte Corporation Crystalline form of a PD-1/PD-L1 inhibitor
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
MX2023005362A (es) 2020-11-06 2023-06-22 Incyte Corp Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.
CN114807038B (zh) * 2022-02-11 2023-11-10 四川大学华西第二医院 一种小鼠淋巴瘤相关成纤维细胞肿瘤细胞HXLyAF-KT及其应用
EP4631503A1 (en) * 2024-04-08 2025-10-15 Molius Saglik Teknolojileri Anonim Sirketi Avl-292 or mk-5108 for use in the treatment of pdac

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2585902T3 (es) * 2006-09-22 2016-10-10 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
CN102428087B (zh) * 2009-04-16 2015-06-17 卡洛斯三世国家癌症研究中心基金会 用作激酶抑制剂的咪唑并吡嗪类化合物
CA2841886C (en) * 2011-07-19 2016-08-16 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
JP2014522860A (ja) * 2011-07-19 2014-09-08 メルク・シャープ・アンド・ドーム・ベー・フェー Btk阻害剤としての4−イミダゾピリダジン−1−イル−ベンズアミドおよび4−イミダゾトリアジン−1−イル−ベンズアミド
CA2931431A1 (en) * 2013-12-05 2015-06-11 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
US20170231995A1 (en) * 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
WO2016106627A1 (en) 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Btk inhibitors
WO2016106623A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Benzamide imidazopyrazine btk inhibitors
MX2017015574A (es) * 2015-06-02 2018-08-09 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.

Also Published As

Publication number Publication date
AU2017383236A1 (en) 2019-06-27
ZA201903932B (en) 2021-01-27
SA519402217B1 (ar) 2022-04-19
BR112019012604A2 (pt) 2019-11-26
EP3558968A1 (en) 2019-10-30
EP3558968B1 (en) 2021-02-03
US20190345164A1 (en) 2019-11-14
MY203083A (en) 2024-06-07
IL267374A (en) 2019-08-29
JP7022131B2 (ja) 2022-02-17
CA3046578A1 (en) 2018-06-28
AU2017383236B2 (en) 2022-02-10
IL267374B (en) 2021-07-29
ES2856248T3 (es) 2021-09-27
CN110291080A (zh) 2019-09-27
MX388457B (es) 2025-03-20
JP2020514264A (ja) 2020-05-21
CN110291080B (zh) 2022-07-08
KR102559851B1 (ko) 2023-07-25
US10858364B2 (en) 2020-12-08
WO2018116259A1 (en) 2018-06-28
CL2019001674A1 (es) 2019-11-08
KR20190095403A (ko) 2019-08-14

Similar Documents

Publication Publication Date Title
MX2019007156A (es) Inhibidores de imidazopirazina de la tirosina cinasa de bruton.
MX2022000711A (es) Inhibidores de parp1.
CY1124061T1 (el) Τρικυκλικη ενωση ως αντικαρκινικοι παραγοντες
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
EA201591591A1 (ru) Соединения карбазола, применяемые в качестве ингибиторов бромодомена
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CL2011001215A1 (es) Compuestos derivados de pirimidina, inhibidores de tirosina quinasa; composiciones farmaceuticas que los comprenden; y su uso en el tratamiento y/o prevencion de cancer, enfermedades inflamatorias y enfermedades autoinmunes.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы
EA201692470A1 (ru) Фармацевтические комбинации
SI3609886T1 (sl) Analogi benzoazepina kot inhibicijska sredstva za brutonovo tirozin kinazo
EA201790276A1 (ru) Новые имидазопиридазиновые соединения и их применение
TW201613577A (en) Pharmaceutical combinations
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
EA201791600A1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
EA201790484A1 (ru) Производные тетрагидрохинолина в качестве ингибиторов бромодомена
AR112448A1 (es) Derivados de xantina sustituidos